Details
Stereochemistry | ACHIRAL |
Molecular Formula | C18H19F3N2S |
Molecular Weight | 352.417 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCCN1C2=C(SC3=C1C=C(C=C3)C(F)(F)F)C=CC=C2
InChI
InChIKey=XSCGXQMFQXDFCW-UHFFFAOYSA-N
InChI=1S/C18H19F3N2S/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21/h3-4,6-9,12H,5,10-11H2,1-2H3
Molecular Formula | C18H19F3N2S |
Molecular Weight | 352.417 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Triflupromazine is antipsychotic and an antiemetic drug (sold under the brand names VESPRIN) which used to management of psychoses. However, this drug was discontinued. Triflupromazine binds to the dopamine D1 and dopamine D2 receptors and inhibits their activity. Moreover, binds the muscarinic acetylcholine receptors (M1 and M2).
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P11229 Gene ID: 1128.0 Gene Symbol: CHRM1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1678146 |
|||
Target ID: P08172 Gene ID: 1129.0 Gene Symbol: CHRM2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/4152054 |
|||
Target ID: CHEMBL2056 |
|||
Target ID: CHEMBL217 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VESPRIN Approved UseUsed mainly in the management of psychoses. Also used to control nausea and vomiting Launch Date-3.87935994E11 |
Doses
Dose | Population | Adverse events |
---|---|---|
800 mg 1 times / day multiple, oral Overdose Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Psychotic disorders Sources: |
|
150 mg 1 times / day multiple, intramuscular Recommended Dose: 150 mg, 1 times / day Route: intramuscular Route: multiple Dose: 150 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Psychotic disorders Sources: |
|
3 mg 1 times / day multiple, intravenous Recommended Dose: 3 mg, 1 times / day Route: intravenous Route: multiple Dose: 3 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Nausea Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
[Four cases of extrapyramidal effects following the treatment of hyperemesis gravidarum with triflupromazin (author's transl)]. | 1976 Apr |
|
Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes. | 1984 Sep |
|
Partition of N-monodemethylated phenothiazine drugs to phosphatidylcholine bilayer vesicles studied by second-derivative spectrophotometry. | 2002 Jun |
|
Activation of Maxi Cl(-) channels by antiestrogens and phenothiazines in NIH3T3 fibroblasts. | 2002 May |
|
Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials. | 2005 Oct 17 |
|
Trypanosoma cruzi dihydrolipoamide dehydrogenase as target for phenothiazine cationic radicals. Effect of antioxidants. | 2006 Sep |
|
Synthesis and antitubercular activity of quaternized promazine and promethazine derivatives. | 2007 Mar 1 |
|
[Derivative spectrophotometric and NMR spectroscopic study in pharmaceutical science]. | 2007 Oct |
|
Simultaneous determination of some phenothiazine derivatives in human blood by headspace solid-phase microextraction and gas chromatography with nitrogen-phosphorus detection. | 2008 Nov-Dec |
|
Rapid method for the determination of tranquilizers and a beta-blocker in porcine and bovine kidney by liquid chromatography with tandem mass spectrometry. | 2009 Apr 1 |
|
Inhibitors of clathrin-dependent endocytosis enhance TGFbeta signaling and responses. | 2009 Jun 1 |
|
The effect of calmodulin antagonists on experimental scoliosis: a pinealectomized chicken model. | 2009 Mar 15 |
|
A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle. | 2010 Feb 23 |
|
Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology. | 2010 Mar 3 |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:01:58 UTC 2023
by
admin
on
Fri Dec 15 15:01:58 UTC 2023
|
Record UNII |
RO16TQF95Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 520.2582
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
||
|
WHO-ATC |
N05AA05
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
||
|
WHO-VATC |
QN05AA05
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
||
|
NCI_THESAURUS |
C740
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
||
|
NCI_THESAURUS |
C29710
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4330
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
10805
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | RxNorm | ||
|
2742
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
TRIFLUPROMAZINE
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
725
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
C66635
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
3407
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
m11123
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | Merck Index | ||
|
205-673-6
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
DTXSID9023704
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
CHEMBL570
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
146-54-3
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
SUB11290MIG
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
9711
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
D014273
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
5568
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
RO16TQF95Y
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
DB00508
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY | |||
|
100000088513
Created by
admin on Fri Dec 15 15:01:58 UTC 2023 , Edited by admin on Fri Dec 15 15:01:58 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |